OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.
The conversation discusses the possibility of transplanting leg and arm hair to the scalp for hair loss treatment. Minoxidil is mentioned as a potential aid for hair growth, but concerns about the effectiveness and appearance of body hair on the head are raised.
A 34-year-old from Patna shared a 5-month update on his hair transplant, which involved 4,200 grafts using the FUE technique to cover the front and mid-scalp. He experienced initial shock loss but now sees natural-looking growth and improved density.
Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.
After 10 months, the user's hairline and midscalp look thick following a 6100 graft FUE hair transplant in Turkey. They plan to address the crown in a few months.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
A user's experience with hair loss and their successful hair transplant using finasteride to halt the loss for seven years, as well as other treatments such as Dut and RU58841 being discussed.
The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.
Landon Donovan recently had a hair transplant, leading to noticeable changes in his appearance. The conversation revolves around his confidence and reactions to his new look.
The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
A user shared their 4-month hair transplant progress with 3740 grafts, showing before and after pictures. They had a generally good experience, except for the anesthesia part.
A user shared their positive experience with a hair transplant at Moart Clinic, involving approximately 10,000 grafts for a new hairline and crown. The procedure was smooth, with no pain, and the user is very satisfied with the results.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
The user had two FUT hair transplants with 4,600 grafts for increased density, costing about $11,000 each, and has been using oral minoxidil and finasteride for over five years without side effects. The results are natural-looking with no visible scarring, and the user finds the procedure valuable despite the cost.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.
Hair transplants in Bangkok are praised for their natural appearance, with a zigzag hairline design being favored over straight lines. The clinic Hairtran and Dr. Patty receive positive feedback, though some users express skepticism about photo filters and the authenticity of results.
A 24-year-old male has been using finasteride for 7 months and noticed thinning hair, especially when wet, and is concerned about the effectiveness of the treatment. Suggestions include continuing finasteride, considering minoxidil, and possibly trying micro-needling.
Adipose fat cells and stem cells may help treat hair loss by restoring the scalp's thickness. Treatments like NanoFat injections and Botox are discussed for their potential to promote hair growth.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
A satirical discussion about a hair transplant, with humorous comments on graft placement and clinic choice. The conversation includes references to a "Rebuild a Scalp Clinic" and jokes about using pubic hair and overharvesting.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.